Rising pancreatic cancer incidence—driven by aging, obesity, smoking—and robust clinical trial pipelines (e.g., VCN‑01 with FDA Fast Track, RenovoRx’s TIGeR‑PaC) propel market growth https://www.datamintelligence.com/research-report/north-america-locally-advanced-pancreatic-cancer-market